We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
National Pharmaceuticals' Lead Therapeutic Drug, GLB333 Receives Financial Grant
News

National Pharmaceuticals' Lead Therapeutic Drug, GLB333 Receives Financial Grant

National Pharmaceuticals' Lead Therapeutic Drug, GLB333 Receives Financial Grant
News

National Pharmaceuticals' Lead Therapeutic Drug, GLB333 Receives Financial Grant

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "National Pharmaceuticals' Lead Therapeutic Drug, GLB333 Receives Financial Grant"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

National Pharmaceuticals Corp. has announced that its lead therapeutic drug, GLB333 was awarded a grant from Canada's National Research Council. The grant will be used toward development methods for large scale manufacturing of the drug.

The grant which is awarded to Globe Laboratories, the licensor of the technology is for $30,000 for this year and can be increased significantly upon completion of preliminary feasibility studies.

National has signed a letter of intent with Globe labs to license GLB333, a drug believed to be effective in vascular regeneration, organ transplant and wound healing. The product may have other therapeutic benefits, including pain management due to muscle injury and trauma.

"We are pleased with this Government financial grant for our product which further endorses the need for its rapid development and commercialization," said Elaine Affleck, President of National Pharmaceuticals Corp.

Advertisement